Compared with placebo, the aldosterone synthase inhibitor lorundrostat lowered blood pressure among patients with uncontrolled hypertension in the TARGET-HTN trial, researchers report. “Blood pressure reduction
A study of evidence-based medicines for 6 cardiovascular diseases (CVDs; atrial fibrillation, heart failure, hyperlipidemia, hypertension, post–acute coronary syndrome secondary prevention, and stable angina) shows
The focus of research on cardiogenic shock (CS) is shifting from acute myocardial infarction (AMI) to heart failure-related CS, according to authors of a review of
In an Intention to Treat audio interview, the lead author of the semaglutide study reported previously in PNN sheds light on how cardiologists came to
In a phase 1 pharmacokinetics and pharmacodynamics trial, muvalaplin was safe and well-tolerated and lowered lipoprotein(a) (Lp[a]) levels up to 65% after 14 days of daily
Combined with clinical risk factors, a protein score was significantly associated with atherosclerotic cardiovascular disease (ASCVD) in primary and secondary events populations, according to a
Compared with placebo in the STEP-HFpEF trial, once-weekly semaglutide 2.4 mg reduced symptoms and physical limitations, improved exercise function, and produced weight loss, investigators report.
Compared with placebo in people with HIV infection, pitavastatin decreased the risk of major adverse cardiovascular events over a median follow-up of 5.1 years, researchers
Aspirin is underused for secondary prevention of cardiovascular disease (CVD), particularly in low-income countries, according to a study of 51 countries with varying per-capita income
Analyzing NHANES (National Health and Nutrition Examination Survey) data from 1999 to 2018, investigators find that a difference in cardiovascular disease (CVD) mortality between Black